Therefore, the present study focuses on the Bcl-2–Beclin 1 complex and takes RCE-4 as a model drug to deeply clarify the molecular mechanisms underlying its anti-cervical cancer effects. This evidence concerns the gene BECN1 and cervical carcinoma.